Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.

228.97 2.53 −1.09%
Market cap
$162.7B
P/E
40.5×
Fwd P/E
29.2×
Dividend yield
0.66%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100

Danaher Corporation 10-Q filed Jul 21, 2026

Fiscal Q2 2026 · Period ended Jun 26, 2026 · Filed · accepted 5:48 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 21, 2026: 33 added · 7 removed · 48 modified; 11 with only figures updated

  1. Modified · •Critical Accounting Estimates

    You should read this discussion along with the Company’s MD&A and audited financial statements and Notes thereto as of and for the year ended December 31, 2025, included in the Company’s 2025 Annual Report and the Company’s Consolidated Condensed Financial Statements and related Notes as of and for the three-month period three and six-month periods ended March 27June 26, 2026 included in this Quarterly Report on Form 10-Q (“Report”).

87 more changes in this Item, word by word, in Powerpack.

Powerpack